CVKD.US Cadrenal Therapeutics, Inc. Common Stock

Healthcare Biotechnology USA Stocks
1.51 USD
Close of Nov 13, 2026
0.8160 12.50
Market cap
USD 5.39M
P/E
-
P/B
1.31x
ROE
-284.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is CVKD.US undervalued?

Graham number

The Graham number of Cadrenal Therapeutics, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Cadrenal Therapeutics, Inc. Common Stock fundamental analysis

No fundamental analysis for Cadrenal Therapeutics, Inc. Common Stock yet.

Cadrenal Therapeutics, Inc. Common Stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Cadrenal Therapeutics, Inc. Common Stock

Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, and atrial f…

Full company profile